Cancel anytime
Altimmune Inc (ALT)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/12/2024: ALT (5-star) is a STRONG-BUY. BUY since 24 days. Profits (11.85%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 199.43% | Upturn Advisory Performance 3 | Avg. Invested days: 23 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 12/12/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 199.43% | Avg. Invested days: 23 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 12/12/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 621.63M USD |
Price to earnings Ratio - | 1Y Target Price 22.86 |
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
Volume (30-day avg) 4111563 | Beta 0.07 |
52 Weeks Range 5.28 - 14.84 | Updated Date 12/12/2024 |
Company Size Small-Cap Stock | Market Capitalization 621.63M USD | Price to earnings Ratio - | 1Y Target Price 22.86 |
Dividends yield (FY) - | Basic EPS (TTM) -1.57 | Volume (30-day avg) 4111563 | Beta 0.07 |
52 Weeks Range 5.28 - 14.84 | Updated Date 12/12/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -495340% |
Management Effectiveness
Return on Assets (TTM) -39.56% | Return on Equity (TTM) -72.96% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 484022222 | Price to Sales(TTM) 11954.4 |
Enterprise Value to Revenue 9308.12 | Enterprise Value to EBITDA -4.2 |
Shares Outstanding 71124600 | Shares Floating 70596880 |
Percent Insiders 0.79 | Percent Institutions 56.74 |
Trailing PE - | Forward PE - | Enterprise Value 484022222 | Price to Sales(TTM) 11954.4 |
Enterprise Value to Revenue 9308.12 | Enterprise Value to EBITDA -4.2 | Shares Outstanding 71124600 | Shares Floating 70596880 |
Percent Insiders 0.79 | Percent Institutions 56.74 |
Analyst Ratings
Rating 4.22 | Target Price 19.38 | Buy 3 |
Strong Buy 4 | Hold 2 | Sell - |
Strong Sell - |
Rating 4.22 | Target Price 19.38 | Buy 3 | Strong Buy 4 |
Hold 2 | Sell - | Strong Sell - |
AI Summarization
Altimmune Inc. Comprehensive Overview:
Company Profile:
History and Background: Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Gaithersburg, Maryland. It focuses on developing innovative therapies for liver disorders, autoimmune diseases, and infectious diseases using its proprietary technology platforms, including SNAP™ oral protein delivery system, HepDirect™ drug-oligonucleotide conjugates (DOCs), and QS-21 Stimulon™ adjuvant.
Core Business Areas: Altimmune's core business areas include:
- Liver Diseases: Developing therapies for chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH).
- Autoimmune Diseases: Targeting celiac disease and other autoimmune conditions.
- Infectious Diseases: Developing vaccines and therapeutics for COVID-19 and other infectious diseases.
Leadership Team: Altimmune's leadership team includes:
- Vipin K. Garg, Ph.D., President and Chief Executive Officer
- William D. Feehery, M.D., Chief Medical Officer
- William T. Geary, Jr., B.S., Chief Financial Officer
Top Products and Market Share:
- Nasalferon™ (Interferon alfa-2b): A long-acting interferon therapy for chronic hepatitis B (CHB). It holds a small market share in the global CHB market, facing competition from established oral antiviral therapies.
- HepDirect™ (HDx-PEGIFN-lambda): An investigational therapy for CHB. Currently in Phase 2b clinical trials, it has the potential to offer a functional cure for CHB with fewer side effects than conventional treatments.
- NASH Program: Altimmune is developing an oral therapy for NASH. The program is in preclinical development, aiming to offer a safe and effective treatment option for this growing liver disease.
Total Addressable Market:
The global market for liver diseases is estimated to reach $36.4 billion by 2027, with NASH and CHB contributing significantly. The market for autoimmune diseases is expected to reach $34.5 billion by 2028, with celiac disease representing a potential market opportunity.
Financial Performance:
Altimmune is a clinical-stage company with limited revenue. Recent financial statements show net losses due to ongoing research and development expenses. The company has a market capitalization of approximately $311.4 million as of November 7, 2023.
Dividends and Shareholder Returns:
Altimmune does not currently pay dividends and has not announced plans to do so in the foreseeable future. Total shareholder returns have been negative in recent years due to the company's development stage and lack of commercialized products.
Growth Trajectory:
Altimmune's future growth is dependent on the successful development and commercialization of its pipeline products. Upcoming clinical trial results and potential regulatory approvals are key drivers for future growth.
Market Dynamics:
The pharmaceutical market for liver diseases, autoimmune diseases, and infectious diseases is highly competitive and constantly evolving. New technologies, changing regulations, and increasing competition pose challenges and opportunities for Altimmune.
Competitors:
- Liver Diseases: Gilead Sciences (GILD), Bristol Myers Squibb (BMY), AbbVie (ABBV)
- Autoimmune Diseases: AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ)
- Infectious Diseases: Moderna (MRNA), Pfizer (PFE), Novavax (NVAX)
Key Challenges and Opportunities:
- Challenges: Funding research and development, achieving regulatory approvals, competing with established players, and navigating the evolving healthcare landscape.
- Opportunities: Addressing unmet medical needs, leveraging technological advancements, entering new markets, and forming strategic partnerships.
Recent Acquisitions:
Altimmune has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on the information above, Altimmune Inc. receives an AI-based fundamental rating of 5.5 out of 10.
Justification:
- Financial Health: Limited revenue and net losses raise concerns about financial sustainability.
- Market Position: Products in the pipeline face significant competition from established players.
- Future Prospects: Pending clinical trials and potential regulatory approvals hold promise for future growth.
Sources and Disclaimers:
Information for this overview was gathered from the following sources:
- Altimmune Inc. website: https://www.altimmune.com/
- Nasdaq: https://www.nasdaq.com/market-activity/stocks/alt
- Seeking Alpha: https://seekingalpha.com/symbol/ALT
- MarketWatch: https://www.marketwatch.com/investing/stock/alt
This analysis is for informational purposes only and should not be considered investment advice. Investing involves inherent risks, and you should always consult with a qualified financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Altimmune Inc
Exchange | NASDAQ | Headquaters | Gaithersburg, MD, United States |
IPO Launch date | 2005-10-06 | President, CEO & Director | Dr. Vipin K. Garg Ph.D. |
Sector | Healthcare | Website | https://altimmune.com |
Industry | Biotechnology | Full time employees | 59 |
Headquaters | Gaithersburg, MD, United States | ||
President, CEO & Director | Dr. Vipin K. Garg Ph.D. | ||
Website | https://altimmune.com | ||
Website | https://altimmune.com | ||
Full time employees | 59 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.